The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...
Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...
Vertex Pharmaceuticals EVP Edward Atkinson sold 1,767 shares for $849,838 on Feb. 25, 2025. This transaction, conducted under ...
While announcing billions of dollars in new U.S. investments, company chief David Ricks called for an extension of 2017 tax ...
Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...
Vertex Pharmaceuticals has been attracting investor attention due to strong recent stock performance. The company's shares ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
The additive manufacturing sector continues to show near-limitless potential. Innovations have taken 3D printers from creating customized figurines all the way to printing entire neighborhoods, ...
RAD Security, a San Francisco-based provider of security for cloud-focused infrastructure, raised $14 million in Series A ...
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results